Back

SGLT2 inhibitors are associated with development of heart failure with improved ejection fraction

1 September 2024 (13:00 - 13:50)
Organised by: Logo
Congress Presentation Part of: Optimisation of heart failure treatment Heart Failure with Reduced Ejection Fraction (HFrEF) ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Xiaoqun Wang

Rui Jin Hospital- Shanghai Jiaotong University School of Medicine, Shanghai (China)

8 More presentations in this session

Presentation thumbnail
Up-titration of Guideline Directed Medical Therapy (GDMT) and the occurrence of side effects in Heart Failure with reduced Ejection Fraction (HFrEF)
Doctor N. Panagiotides (Vienna, AT)
Abstract Slides Video
Presentation thumbnail
Visit-to-visit changes in heart rate in heart failure: a pooled participant-level analysis of the PARADIGM-HF and PARAGON-HF trials
Doctor H. Lu (Lausanne, CH)
Abstract Slides Video
Presentation thumbnail
Use and associations with mortality/morbidity of guideline-directed medical therapy use in heart failure with improved ejection fraction: a PS-matched analysis from the swedish heart failure registry
Doctor C. Basile (Stockholm, SE)
Abstract Slides Video
Presentation thumbnail
Survival benefit of guideline-directed medical therapy in elderly patients with heart failure with reduced ejection fraction: a systematic review and meta-analysis
Doctor E. Tan (Singapore, SG)
Abstract Slides Video
Presentation thumbnail
Differences in the optimization of pharmacological treatment in patients with heart failure and reduced ejection fraction and advanced chronic kidney disease.
Doctor A. Recio Mayoral (Seville, ES)
Abstract Slides Video

Access the full session

Session thumbnail
Optimisation of heart failure treatment

The Event

Event poster

ESC Congress 2024

1 September 2024 13:00 CET
You may be interested in
thumbnail
Congress Presentation
Hemoglobin, hematocrit and heart failure: the SGLT2 inhibitor connection
thumbnail
Congress Session
Further Insights into SGLT2i treatment for heart failure
thumbnail
Congress Presentation
The effects of SGLT2 inhibitors in patients with preserved ejection fraction heart failure and type 2 diabetes: A randomized case-control study

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources